Urisan

Quick links to important sections

Urisan

Method of action: Bactericidal

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urisan

Quick Facts

Property Description
Active ingredient Pipemidic Acid
Form Hard Capsules or Film-coated Tablets
Pharmacological class Quinolone Antibacterial
Common purpose Systemic Anti-infective Agent
Origin Synthetic

What is Urisan?

Urisan is a prescription-only medicine defined by its single active ingredient, Pipemidic Acid, and its classification as a quinolone antibacterial agent. This substance belongs to the first-generation quinolones, representing an early class of synthetic chemotherapeutic compounds. Its origin is purely synthetic, a factor essential to understanding its mechanism and utility as a targeted anti-infective. The trade name Urisan often signifies a formulation specifically focused on the broad category of urinary anti-infective use.

What Type of Medicine is Urisan?

Urisan is classified as a systemic anti-infective agent that functions as a quinolone antibacterial. Its active substance, Pipemidic Acid, is structurally an aza-analogue of nalidixic acid and is listed as an antimicrobial agent within the Anatomical Therapeutic Chemical (ATC) Classification System. This classification recognizes its role as an agent used against infectious organisms. The medicine is designed for oral route of administration to achieve systemic therapeutic concentrations throughout the body.

Active Ingredient and Dosage Form

The medicine is a single active ingredient product containing Pipemidic Acid, which is formulated for oral administration as hard capsules or film-coated tablets. This solid oral dosage form is composed of the active substance combined with solid pharmaceutical excipients necessary for the tablet's structure and stability. The use of a defined, precise solid form ensures that a specific, measured quantity of Pipemidic Acid is reliably delivered to the body for consistency and bioavailability.

General Purpose and Mechanism Principle

The general purpose of Urisan is to serve as an anti-infective agent by eliminating susceptible bacterial populations within the body. Pipemidic Acid achieves this by demonstrating bactericidal activity, meaning it directly causes the destruction and death of bacterial cells. This effect stems from the drug fundamentally blocking the essential ability of the bacteria to copy and repair their own DNA, swiftly controlling the infectious process.

What side effects are possible with Urisan?

Possible side effects and safety information

The safety profile for medicines containing Pipemidic Acid is fundamentally defined by the risks associated with its class, quinolone antibacterials. This profile is characterized by the potential for serious, disabling, and potentially irreversible adverse reactions that affect multiple body systems.


Officially Documented Adverse Reactions

The adverse reactions associated with this medicine are classified into System-Organ Classes (SOC) in regulatory documentation. Common, expected adverse reactions often involve the Gastrointestinal System (such as nausea, vomiting, diarrhea, and abdominal pain) and Nervous System (including headache and dizziness).

Serious reactions documented for this antibacterial class, which led to a suspension of the marketing authorization in the European Union, include effects categorized under:

  • Musculoskeletal and Connective Tissue Disorders: Such as tendinitis and tendon rupture, which may be delayed several months after treatment ends.
  • Nervous System Disorders: Including peripheral neuropathy (tingling, numbness, or weakness) and severe central nervous system effects like confusion and toxic psychosis.
  • Immune System Disorders: Serious hypersensitivity reactions, which can occur following the first dose.

Population-Specific Safety Considerations

The official labeling notes that certain populations have an increased risk of adverse reactions, particularly tendon damage. This includes elderly patients, individuals with renal impairment, and patients who have received an organ transplant. The medicine is generally contraindicated for use in children and pregnant women due to the potential for arthropathy.


Safety Constraints

The most significant regulatory constraint is the suspension of Pipemidic Acid's marketing authorization across the EU due to an unfavorable benefit-risk balance. Additionally, patients are advised to avoid excessive exposure to sunlight or UV radiation due to the risk of phototoxicity, a documented skin reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Urisan (Pipemidic Acid) focuses on the required medical management following a massive ingestion of the drug, rather than a detailed list of clinical symptoms. As of the time of official product characteristic summaries, no incidents of poisoning have been formally reported for this substance.

Manifestations and Emergency Action

If a massive dose is suspected or if clinical signs related to excessive absorption occur, immediate medical attention is required. Management is supportive and procedural, as no specific antidote for Pipemidic Acid is documented in the official labeling.

Management Requirement Officially Documented Action
If recent ingestion Gastric lavage
If absorption has occurred Forced diuresis
If clinically necessary Resuscitation

These actions must be performed by medical professionals in a clinical setting. The requirement to seek urgent medical help is based on the necessity to rapidly initiate these officially described supportive measures. There are no population-specific overdose considerations explicitly stated in the official regulatory documents for patients such as the elderly or those with existing kidney conditions.

Therapeutic Uses of Urisan

What Urisan Treats: Main Uses and Benefits

The therapeutic use of this medicine is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving acute or disruptive symptom patterns within the urinary system. This class of medicine is generally relevant in contexts involving heightened systemic burden associated with conditions where symptoms may intensify temporarily.


Symptom Management and Clinical Scenarios

The medicine is commonly used across conditions presenting with acute episodes of lower urinary tract infections, including cystitis and urethritis. It is used for managing symptoms that interfere with daily comfort, such as dysuria (pain or burning during urination), frequency, and nocturia. The medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, such as Pyelonephritis (kidney infection) and Prostatitis.

“It is often used during phases when symptoms become more noticeable and supportive symptom management is appropriate.”

In managing these acute and recurrent symptomatic clusters, the medicine contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

Quick Fact Support for Symptom Management
Primary Focus Symptoms related to physical discomfort or heightened physiological activity.
Symptom Easing Dysuria, frequency, and lower abdominal discomfort.
Patient Benefit Supports patients during episodes of heightened discomfort.

Regulatory References

  1. European Medicines Agency (EMA) on Quinolone Restrictions

Eligibility and Restrictions for Use

Urisan (Pipemidic Acid) eligibility is strictly defined by official regulatory guidelines and is limited to the adult patients where the medicine remains authorized by national authorities. A major regulatory restriction is the suspension of the medicine's marketing authorization across the European Union.

Use is contraindicated and absolutely prohibited for several population groups, including individuals with a known hypersensitivity to Pipemidic Acid or to the quinolone class of antibacterials. Patients with a documented history of tendinopathy related to any previous quinolone use must also not use this medicine. Furthermore, the label explicitly states that use is contraindicated in children, adolescents, pregnant women, and lactating (breasfeeding) women.

Regarding organ function, eligibility is generally maintained for certain patients: regulatory information indicates that those with mild renal insufficiency (specifically, CrCl ge 30 ml/min) or hepatic impairment typically do not require dose adjustments, thus maintaining their eligibility.

What should I know about interactions with other medicines?

Official Interactions with other Medicines and Products

Regulatory documentation for Urisan (Pipemidic Acid) identifies several interaction categories affecting co-administered medicines and specific product types. No drug combination is formally listed as an absolute contraindication in the primary prescribing information.

Interacting Product Category Regulatory Statement on Interaction
Theophylline Reduced clearance of Theophylline is documented, consistent with inhibition of the CYP1A2 enzyme, potentially leading to elevated plasma levels.
Oral Anticoagulants Urisan may potentiate the effects of coumarin anticoagulants, requiring careful monitoring.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) The risk of central nervous system (CNS) excitation effects, including the potential for seizures, may be heightened when co-administered.
Probenecid Plasma concentrations of Pipemidic Acid may be altered due to interference with its renal excretion.

Restrictions and Administration Adjustments

Interaction constraints are imposed for certain products to prevent reduced drug exposure:

  • Mineral-Containing Products: The co-administration of Urisan with antacids or supplements that contain polyvalent cations (such as magnesium, aluminum, calcium, iron, or zinc) results in significantly reduced absorption of Urisan. To mitigate this effect, official labeling mandates that Urisan must be administered at least two hours before or after these mineral-containing products.

Population-Specific Notes

The combined use of Urisan with corticosteroids is associated with an increased risk of tendonitis and tendon rupture. This risk is specifically noted to be heightened in older patients.

Mechanism of Action

Urisan works through a dual pharmacodynamic mechanism that targets the involuntary control elements of the urinary bladder, resulting in smooth muscle relaxation and modulation of the involuntary micturition reflex.

Muscarinic Receptor Blockade

Urisan's main action is as a competitive antagonist at Muscarinic Acetylcholine Receptors, particularly M₁ and M₂, located on the detrusor smooth muscle. By blocking the binding of the excitatory neurotransmitter acetylcholine (ACh), this mechanism dampens the parasympathetic cholinergic signaling that initiates involuntary detrusor contractions. This action contributes to a decrease in detrusor muscle pressure and excitability.

Direct Spasmolytic Activity

In addition to receptor blockade, Urisan possesses a direct, non-specific spasmolytic (muscle relaxing) property on the smooth muscle fiber, potentially through the modulation of intracellular calcium (Ca²⁺) regulation or enzyme activity like Phosphodiesterases (PDEs). This secondary mechanism reinforces the primary effect, contributing to a generalized relaxation of the bladder wall, which alters the passive elastic properties of the bladder wall and permits greater volume accommodation.

Peripheral Micturition Reflex Dampening

These combined effects concentrate on the peripheral efferent arm of the micturition reflex arc. By interrupting the signal from the nerve to the muscle and directly relaxing the tissue, Urisan modulates the activity within this regulatory system. The resulting physiological change includes a decrease in detrusor muscle contractility and an increase in the volume the bladder can accommodate. This modulation of the reflex arc influences the physiological dynamics of bladder filling.

Dosage and Administration Information

How Urisan is Used: Official Administration Guidelines

The usage of Urisan (Pipemidic Acid) follows a standardized method of intake for approved indications.


Administration Scope

The route for this medicine is oral, typically delivered as 400 mg film-coated tablets or hard capsules. The established dosing regimen for adults specifies a standard intake of 400 mg per dose, administered twice daily (BID). This frequency results in a total daily dose of 800 mg of the active substance. The tablets are swallowed whole and taken with a full glass of water as part of the administration process.

Contextual Intake and Usage Restrictions

The timing of Urisan administration occurs after meals. This timing establishes the relationship between intake and the patient’s daily routine.

Regarding specific populations, the medicine's use is not approved for children and adolescents. Furthermore, no dosage adjustment is specified for patients with severe renal or hepatic impairment, structuring the administration for these specific conditions.

Procedural Structure

The procedure involves taking the intact oral dose following a meal, with the second dose occurring approximately twelve hours later to maintain the twice-daily schedule. These procedural elements, such as swallowing the tablet whole with a full glass of water, are components of the standardized administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urisan (Pipemidic Acid)

This section provides an accessible overview of the official research studies conducted for Urisan, explaining what types of clinical evidence exist and what outcomes researchers have chosen to monitor. This summary focuses only on the structure of the evidence and does not provide clinical or usage advice.


Evidence for Uncomplicated Lower Urinary Tract Infections (UTIs)

The main body of research for Urisan has been applied in studies examining patient-reported experiences and microbiological changes for acute, uncomplicated lower urinary tract infections (UTIs). These conditions characterized by fluctuating or episodic manifestations, like cystitis, were often evaluated in randomized controlled trials (RCTs) and other comparative studies. These trials monitored changes in symptoms in adult women who met specific criteria for infection.

Research monitored outcomes measured during the study period related to physical discomfort, such as burning or pain during urination. The studies also examined the elimination rate of the specific bacteria associated with the infection. Findings describe patterns observed in these studies, sometimes comparing the drug's effects to other standard antibacterial agents.


Research in More Complex Urinary Tract Situations

Research has been studied for use in more complicated urinary tract situations, including conditions involving periods of heightened symptoms such as kidney infections (pyelonephritis) and inflammation of the prostate (prostatitis). These studies consisted of smaller, descriptive clinical trials that lacked large-scale, controlled comparisons.

These research scenarios explored short-term symptom changes and the elimination of pathogens in these more severe settings. The research describes patterns observed in how patients reported their experience during these difficult episodes. However, the evidence derived from these settings often had follow-up durations that were limited, and the sample sizes were modest, contributing to a research base that is not as extensive or robust as the data for uncomplicated UTIs.

Key Studies & References WHO Anatomical Therapeutic Chemical (ATC) Classification System: J01MB04 (Pipemidic Acid)

Frequently Asked Questions (FAQ)

Common questions about Urisan (FAQ)


Q: Are there any common foods or drinks that make Urisan less effective?

Official product information states that mineral-containing products can significantly reduce the absorption of Urisan. This includes antacids or supplements that contain polyvalent cations like magnesium, aluminum, calcium, iron, or zinc. The labeling advises that Urisan be administered at least two hours before or two hours after consuming these mineral-containing products.


Q: Can children take Urisan, and if so, at what age?

Regulatory documents state that the use of Urisan is explicitly contraindicated and absolutely prohibited for children and adolescents. Its use is limited to adults and is not intended for pediatric populations. Its use is also prohibited for pregnant and breastfeeding women.


Q: Can Urisan cause dizziness or make it unsafe to drive?

Dizziness and headache are listed as common adverse reactions associated with this medicine. These adverse effects are noted in the labeling as potentially impairing the ability to drive or operate machinery, as they are central nervous system effects.


Q: Does Urisan contain any gluten, lactose, or common allergens?

The official product documentation, found in the excipient list (Section 6.1 of the SmPC), provides a full breakdown of all substances used to make the tablets or capsules. Specific details on allergens, such as gluten or lactose, can be verified by consulting the full list of excipients in the official product documentation.


Q: How should Urisan be stored—does it need to be refrigerated?

According to official regulatory instructions, Urisan must be stored at room temperature. Official instructions specify that the medicine should be kept in its original protective packaging, sheltered from light, to maintain its stability.


Q: Why do some people take Urisan for bladder irritation?

Urisan's pharmacological mechanism includes blocking muscarinic receptors on the bladder muscle and possessing direct spasmolytic (muscle-relaxing) properties. This action contributes to a decrease in detrusor muscle pressure and excitability, which relates to the physiological dynamics of bladder filling.


Q: Is it possible to take Urisan and still have persistent symptoms?

The medicine’s marketing authorization was suspended in the European Union due to an unfavorable benefit-risk balance. This regulatory action reflects that authorities determined the benefit-risk balance to be unfavorable, which means persistent symptoms or adverse events were a factor.


Q: Will Urisan interfere with sleep or cause insomnia?

Central nervous system disturbances are included as potential serious adverse reactions associated with this class of antibacterial agents. While insomnia is not always explicitly listed, these effects can impact the central nervous system.


Q: What does the research say about Urisan's use in preventing recurrence?

Official research primarily focuses on the treatment of acute, uncomplicated lower urinary tract infections (UTIs) and examines short-term symptom outcomes. Research studies have primarily focused on treatment for acute infections and short-term outcomes, rather than long-term use or prevention of recurrence (prophylaxis).


Q: Is Urisan a probiotic or does it work differently?

Urisan is classified as a synthetic quinolone antibacterial agent. It is designed to be bactericidal—it directly destroys and kills bacterial cells—which is a mechanism fundamentally different from a probiotic, which introduces beneficial live microorganisms to the body.


Q: Does Urisan cause headaches or migraines?

Headache is documented in official sources as a common, expected adverse reaction affecting the Nervous System. Specific mention of the term 'migraine' is not typically detailed in the adverse reaction lists.


Q: Can Urisan be crushed or opened if someone has trouble swallowing pills?

The official administration protocol requires the tablets to be swallowed whole with a full glass of water. The administration protocol specifies that the tablets are to be swallowed whole with a full glass of water. Altering the dosage form may affect its required action or absorption.


Q: What is the recommended age range for Urisan use, according to the manufacturer?

Urisan is authorized for use only in adult patients. Official prescribing information explicitly states that the use of Urisan is not approved for children and adolescents.


Q: Is Urisan suitable for vegetarians or vegans?

The official product documentation provides a comprehensive list of all excipients and substances used to make the hard capsules or film-coated tablets. The full list of excipients in the official product documentation can be reviewed to verify the components for suitability with vegetarian or vegan diets.


Q: Are there different strengths or formulations of Urisan available?

Urisan is typically delivered as a standard formulation of 400 mg film-coated tablets or hard capsules. This solid oral dosage form ensures consistent delivery of the active ingredient, Pipemidic Acid.


Q: Can Urisan affect or interfere with having a fever?

Urisan is classified as a systemic anti-infective agent, and its purpose is to eliminate susceptible bacterial populations that cause infection. This action against the underlying infection can influence the presence or severity of associated symptoms like fever.


Q: Do I need to change my diet while taking Urisan?

Regulatory information specifies that Urisan should be taken after meals. The only strict dietary constraint relates to the timing of mineral-containing products like antacids or supplements, which must be separated by at least two hours to prevent reduced absorption.


Q: Has Urisan been studied in diverse patient populations?

Clinical studies have involved adult women with uncomplicated lower UTIs and men with prostatitis. The research describes patterns observed in these groups; however, specific details regarding ethnic or racial diversity within the study populations are not typically included in the overview of evidence.


Q: Why is hydration often emphasized when taking Urisan?

The official administration procedure mandates that the oral dose must be taken with a full glass of water. This procedural constraint is essential to ensure proper intake and absorption of the medicine, supporting its function as a targeted anti-infective.


Q: What's the difference between Urisan and other common urinary tract supplements?

Urisan is a prescription-only quinolone antibacterial agent that works by killing bacterial cells, and it is classified as a systemic anti-infective. This mechanism and regulatory status differentiate it from most common urinary tract supplements, which are often non-prescription and function as dietary aids.


Q: Can Urisan be taken with pain relievers like ibuprofen or acetaminophen?

Official documentation indicates that co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes ibuprofen, may increase the risk of central nervous system excitation effects, potentially leading to seizures. Official labeling contains details on specific interactions.


Q: What makes Urisan different from a simple cranberry supplement?

Urisan is a prescription-only quinolone antibacterial agent that works as a bactericide, meaning it directly kills bacterial cells to treat an infection. Cranberry products, by contrast, are typically dietary supplements aimed at prevention or maintenance, and do not possess the same drug classification or mechanism of action.


Q: What if I experience a rash after starting Urisan?

The medicine’s safety profile includes the risk of serious hypersensitivity reactions, such as severe rash, which can sometimes occur even after the first dose. Patients should be aware of the potential for serious immune system disorders related to the quinolone antibacterial class.

How should Urisan be stored and disposed of?

How to Store and Dispose of Urisan?

The storage and disposal of Urisan (Pipemidic Acid) must strictly adhere to the conditions mandated by official regulatory documentation to ensure product stability and safety.

Storage Requirements

Urisan must be stored at room temperature. A key requirement is that the product must be sheltered from light, which necessitates keeping the medicine in its original protective packaging. The official shelf-life for the product is 3 years when stored under these specified conditions.

Disposal Instructions

Unused or expired Urisan should be disposed of through a drug take-back program or an authorized collector. If such a program is not available, the medicine must be prepared for disposal in household trash by first mixing it with an unappealing substance, such as dirt or used coffee grounds, and then sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urisan found in:

A-Z Index: